Background: Challenges remain in determining the most effective treatment strategies and identifying patients who would benefit from adjuvant or neoadjuvant therapy in renal cell carcinoma. The objective of this review is to provide a comprehensive overview of biomarkers in metastatic renal cell carcinoma (mRCC) and their utility in prediction of treatment response, prognosis, and therapeutic monitoring in patients receiving systemic therapy for metastatic disease. Methods: A systematic literature search was conducted using the PubMed database for relevant studies published between January 2017 and December 2022. The search focused on biomarkers associated with mRCC and their relationship to immune checkpoint inhibitors, targeted therapy, and VEGF inhibitors in the adjuvant, neoadjuvant, and metastatic settings. Results: The review identified various biomarkers with predictive, prognostic, and therapeutic monitoring potential in mRCC. The review also discussed the challenges associated with anti-angiogenic and immune-checkpoint monotherapy trials and highlighted the need for personalized therapy based on molecular signatures. Conclusion: This comprehensive review provides valuable insights into the landscape of biomarkers in mRCC and their potential applications in prediction of treatment response, prognosis, and therapeutic monitoring. The findings underscore the importance of incorporating biomarker assessment into clinical practice to guide treatment decisions and improve patient outcomes in mRCC.
背景：在肾细胞癌治疗中，如何确定最有效的治疗策略以及识别哪些患者能从辅助或新辅助治疗中获益仍面临挑战。本综述旨在全面概述转移性肾细胞癌（mRCC）的生物标志物及其在预测转移性疾病患者接受全身治疗后的治疗反应、预后和治疗监测中的应用价值。方法：通过PubMed数据库对2017年1月至2022年12月期间发表的相关研究进行系统性文献检索，重点关注与mRCC相关的生物标志物及其在辅助、新辅助和转移治疗背景下与免疫检查点抑制剂、靶向治疗和VEGF抑制剂的关系。结果：本综述确定了多种在mRCC中具有预测、预后和治疗监测潜力的生物标志物，同时讨论了抗血管生成治疗和免疫检查点单药治疗试验面临的挑战，并强调了基于分子特征进行个体化治疗的必要性。结论：本综述为mRCC生物标志物的研究现状及其在预测治疗反应、预后评估和治疗监测中的潜在应用提供了重要见解。研究结果强调了将生物标志物评估纳入临床实践以指导mRCC治疗决策、改善患者预后的重要意义。
肿瘤(癌症)患者之家